HeartFlow, Inc. (HTFL) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Rick Wise.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rick Wise’s rating is based on HeartFlow, Inc.’s innovative technology and promising growth prospects. The company’s FFR CT and Plaque Analysis technology is seen as a game-changer in coronary artery disease management, providing significant value to patients, physicians, and hospitals. This technology enhances decision-making, leading to improved procedure efficiency and economic benefits.
Additionally, HeartFlow’s strong financial performance, with a 38% revenue growth and 75% gross margins in the first half of 2025, supports the Buy rating. The anticipated reimbursement milestone for their plaque analysis technology is expected to further drive growth. With increasing adoption of their technology and expanding commercial presence, HeartFlow is well-positioned for sustained growth and improved margins in the coming years.
In another report released today, Piper Sandler also initiated coverage with a Buy rating on the stock with a $38.00 price target.